Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance

Objectives: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance. Material and Method: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radioth...

Full description

Saved in:
Bibliographic Details
Main Authors: Bandit Chumworathayi, Prapaporn Suprasert, Kittipat Charoenkwan, Jatupol Srisomboon, Chailert Phongnarisorn, Sitticha Siriaree, Chalong Cheewakriangkrai, Jaruwan Tantipalakorn, Chamnan Kiatpeerakul, Aree Pantusart
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645215997&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62326
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-62326
record_format dspace
spelling th-cmuir.6653943832-623262018-09-11T09:25:41Z Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance Bandit Chumworathayi Prapaporn Suprasert Kittipat Charoenkwan Jatupol Srisomboon Chailert Phongnarisorn Sitticha Siriaree Chalong Cheewakriangkrai Jaruwan Tantipalakorn Chamnan Kiatpeerakul Aree Pantusart Medicine Objectives: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance. Material and Method: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin - in patients with high-risk cervical cancer FIGO stage I-IIA after surgery. Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled. The patients also had to have an absolute neutrophil count of at least 1,500 cells per cubic millimeter, a platelet count of at least 75,000 cells per cubic millimeter, a creatinine clearance higher than 40 milliliter per minute, and adequate hepatic function. All patients received external-beam radiotherapy according to a strict protocol. Patients were randomly assigned to receive one of two chemotherapy regimens: 75 mg per square meter of cisplatin on days 1, 22, 43 and 64 or every three weeks for 4 cycles (group 1) or 40 mg per square meter of cisplatin per week for six cycles (group 2). Results: The analysis included 40 women. The first group that received three-weekly cisplatin had a higher rate of incomplete and delayed treatments than the second group that received weekly cisplatin (p < 0.001 and p = 0.0236 respectively). The relative risks of delayed courses were 2.06 (95 percent confidence interval, 1.15 to 3.68) for group 1, compared with group 2. The toxicity-related incomplete treatments rate and G-CSF doses used were significantly higher in group 1 than in group 2. Conclusion: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery. 2018-09-11T09:25:41Z 2018-09-11T09:25:41Z 2005-11-01 Journal 01252208 01252208 2-s2.0-33645215997 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645215997&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/62326
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Bandit Chumworathayi
Prapaporn Suprasert
Kittipat Charoenkwan
Jatupol Srisomboon
Chailert Phongnarisorn
Sitticha Siriaree
Chalong Cheewakriangkrai
Jaruwan Tantipalakorn
Chamnan Kiatpeerakul
Aree Pantusart
Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
description Objectives: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance. Material and Method: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin - in patients with high-risk cervical cancer FIGO stage I-IIA after surgery. Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled. The patients also had to have an absolute neutrophil count of at least 1,500 cells per cubic millimeter, a platelet count of at least 75,000 cells per cubic millimeter, a creatinine clearance higher than 40 milliliter per minute, and adequate hepatic function. All patients received external-beam radiotherapy according to a strict protocol. Patients were randomly assigned to receive one of two chemotherapy regimens: 75 mg per square meter of cisplatin on days 1, 22, 43 and 64 or every three weeks for 4 cycles (group 1) or 40 mg per square meter of cisplatin per week for six cycles (group 2). Results: The analysis included 40 women. The first group that received three-weekly cisplatin had a higher rate of incomplete and delayed treatments than the second group that received weekly cisplatin (p < 0.001 and p = 0.0236 respectively). The relative risks of delayed courses were 2.06 (95 percent confidence interval, 1.15 to 3.68) for group 1, compared with group 2. The toxicity-related incomplete treatments rate and G-CSF doses used were significantly higher in group 1 than in group 2. Conclusion: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery.
format Journal
author Bandit Chumworathayi
Prapaporn Suprasert
Kittipat Charoenkwan
Jatupol Srisomboon
Chailert Phongnarisorn
Sitticha Siriaree
Chalong Cheewakriangkrai
Jaruwan Tantipalakorn
Chamnan Kiatpeerakul
Aree Pantusart
author_facet Bandit Chumworathayi
Prapaporn Suprasert
Kittipat Charoenkwan
Jatupol Srisomboon
Chailert Phongnarisorn
Sitticha Siriaree
Chalong Cheewakriangkrai
Jaruwan Tantipalakorn
Chamnan Kiatpeerakul
Aree Pantusart
author_sort Bandit Chumworathayi
title Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
title_short Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
title_full Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
title_fullStr Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
title_full_unstemmed Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance
title_sort weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage i-iia cervical cancer after surgery: a randomized comparison of treatment compliance
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645215997&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62326
_version_ 1681425786024755200